Dr. Gregg Morin received his PhD in Biochemistry from the University of Colorado, Boulder in 1988. Following a postdoctoral fellowship in the Department of Molecular Biophysics and Biochemistry at Yale University and an assistant professorship at the University of California, Davis, Dr. Morin was the Director of the Department of Molecular Biology and Biochemistry at Geron Corporation. In 2004, he joined Canada’s Michael Smith Genome Sciences Centre where he is currently the Head of Proteomics. He is also an Adjunct Professor in the Department of Molecular Biology and Biochemistry at Simon Fraser University and an Associate Professor in the Department of Medical Genetics at the University of British Columbia. Finally, he was the founding Scientific Director of the BC Proteomics Network, which provides proteomic support services and education to BC scientists.
Dr Morin’s achievements include pioneering the use of mass spectrometry for analyzing protein-protein interactions involved in disease, mapping the interactions within the TNFα inflammatory pathway. He was the first to observe human telomerase activity and developed assays to detect and measure it. Based on these discoveries, Geron Corporation was formed. There, his group demonstrated that hTERT expression is sufficient to immortalize human cells in a landmark Science publication in 1998. Dr. Morin is listed as an inventor on 64 patents related to these telomerase discoveries and applications.
As Head of the Proteomics Platform at Canada’s Michael Smith Genome Sciences Centre, Dr. Morin’s role is to advance mass spectrometry-based oncology research with other investigators at BC Cancer and other institutions. This includes developing proteomic methods for quantitative global proteome profiling of clinical and research samples, basic and aberrant protein function research, and the comprehensive analysis of post-translational modifications (e.g., phospho, ubiquitin, methyl, acetyl). His expertise is in advanced proteomics methods, biochemistry, and RNA processing.
Dr. Gregg Morin has coauthored >70 publications (including reviews) that have been cited >19,000 times, and has 64 issued patents worldwide (37 in USA) related to his telomerase research.